Security Snapshot

Evolent Health, Inc. - Class A Common Stock, par value $0.01 per share (EVH) Institutional Ownership

CUSIP: 30050B101

13F Institutional Holders and Ownership History from Q2 2015 to Q1 2026

Latest Period

Q4 2025

Institutions Reporting

210

Shares (Excl. Options)

120,526,738

Price

$4.00

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place.

Create free account to save this page Review latest holder period
Type / Class
Equity / Class A Common Stock, par value $0.01 per share
Symbol
EVH on NYSE
Shares outstanding
112,318,617
Price per share
$2.28
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
120,526,738
Total reported value
$482,110,451
% of total 13F portfolios
0%
Share change
-15,100,003
Value change
-$146,980,793
Number of holders
210
Price from insider filings
$2.28
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Quick Takeaways

  • EVH - Evolent Health, Inc. - Class A Common Stock, par value $0.01 per share is tracked under CUSIP 30050B101.
  • 210 institutions reported positions in Q4 2025.
  • 8 significant owners is listed from Schedule 13D/13G reporting.

What Changed

  • Holder count moved from 210 to 16 between Q4 2025 and Q1 2026.
  • Reported value moved from $482,110,451 to $822,712.

Why This Matters

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Source Evidence

Source: SEC Form 13F

Latest holder context comes from 210 institutions filings for Q4 2025.

Open SEC Evidence

Investment Quick Answers

What is CUSIP 30050B101?
CUSIP 30050B101 identifies EVH - Evolent Health, Inc. - Class A Common Stock, par value $0.01 per share in SEC 13F datasets.

Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.

Significant Owners of Evolent Health, Inc. - Class A Common Stock, par value $0.01 per share (EVH) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
CADIAN CAPITAL MANAGEMENT, LP 9.3% $106,218,923 10,794,606 Cadian Capital Management, LP 31 Mar 2025
MORGAN STANLEY 8.1% +16% $37,755,903 +$3,682,702 9,097,808 +11% Morgan Stanley 31 Dec 2025
VANGUARD GROUP INC 8% $35,656,260 8,914,065 The Vanguard Group 31 Dec 2025
Boehler Adam 5.2% $49,204,401 5,816,123 Rubicon OP GP II LP 13 Nov 2025
RA CAPITAL MANAGEMENT, L.P. 3.1% $35,199,618 3,577,197 RA Capital Management, L.P. 31 Dec 2024
FMR LLC 0.7% -91% $3,003,548 -$34,663,704 750,887 -92% FMR LLC 31 Dec 2025
WELLINGTON MANAGEMENT GROUP LLP 0.4% -96% $5,016,947 -$113,228,542 442,802 -96% Wellington Management Group LLP 30 Jun 2025
EVENTIDE ASSET MANAGEMENT, LLC 0% -108% $7,109 -$26,106,812 1,713 -100% Eventide Asset Management, LLC 31 Dec 2025

As of 31 Dec 2025, 210 institutional investors reported holding 120,526,738 shares of Evolent Health, Inc. - Class A Common Stock, par value $0.01 per share (EVH). This represents 107% of the company’s total 112,318,617 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Evolent Health, Inc. - Class A Common Stock, par value $0.01 per share (EVH) together control 87% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
CADIAN CAPITAL MANAGEMENT, LP 9.9% 11,085,455 -5.5% 3.2% $44,341,820
BlackRock, Inc. 9.2% 10,331,551 +11% 0% $41,326,204
MORGAN STANLEY 8.3% 9,278,123 +16% 0% $37,112,494
VANGUARD GROUP INC 7.9% 8,914,065 -19% 0% $35,656,260
UBS Group AG 5.4% 6,109,618 +80% 0% $24,438,472
Rubicon Founders LLC 5.2% 5,816,123 0% 15% $23,264,492
Engaged Capital LLC 5% 5,563,912 -1.8% 5.7% $22,255,648
D. E. Shaw & Co., Inc. 4.7% 5,269,302 +92% 0.02% $21,077,208
JANE STREET GROUP, LLC 2.6% 2,952,947 +105% 0.01% $11,811,788
JPMORGAN CHASE & CO 2.6% 2,947,686 -26% 0% $11,790,744
STATE STREET CORP 2.6% 2,941,761 -1.1% 0% $11,767,044
GEODE CAPITAL MANAGEMENT, LLC 2.4% 2,733,444 -0.86% 0% $10,935,890
Rock Springs Capital Management LP 2.4% 2,675,000 -9.3% 0.55% $10,700,000
MAVERICK CAPITAL LTD 2.3% 2,539,930 +6% 0.11% $10,159,720
DIMENSIONAL FUND ADVISORS LP 2.1% 2,307,784 -8% 0% $9,231,434
JACOBS LEVY EQUITY MANAGEMENT, INC 2% 2,268,872 +28% 0.04% $9,075,488
CITADEL ADVISORS LLC 1.7% 1,855,017 -19% 0.01% $7,420,068
GOLDMAN SACHS GROUP INC 1.6% 1,833,495 +108% 0% $7,333,980
TWO SIGMA INVESTMENTS, LP 1.4% 1,537,524 +81% 0.01% $6,150,096
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 1.3% 1,516,215 +16% 0% $6,064,860
MILLENNIUM MANAGEMENT LLC 1.3% 1,475,042 +223% 0% $5,900,168
Hudson Bay Capital Management LP 1.3% 1,460,000 +153% 0.03% $5,840,000
Tejara Capital Ltd 1.2% 1,331,441 2.2% $5,325,764
Balyasny Asset Management L.P. 1.1% 1,261,007 +622% 0.01% $5,044,028
Rock Point Advisors, LLC 1.1% 1,190,156 +22% 1.2% $4,760,624

Institutional Holders of Evolent Health, Inc. - Class A Common Stock, par value $0.01 per share (EVH) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q1 361,776 $822,712 -$294,680 $2.28 16
2025 Q4 120,526,738 $482,110,451 -$146,980,793 $4.00 210
2025 Q3 135,659,696 $1,147,817,881 +$12,305,118 $8.46 237
2025 Q2 131,673,312 $1,482,570,130 +$78,519,495 $11.26 218
2025 Q1 125,716,823 $1,190,564,177 +$20,137,898 $9.47 222
2024 Q4 122,283,963 $1,375,271,472 -$248,054,960 $11.25 237
2024 Q3 129,270,440 $3,653,744,995 +$36,997,360 $28.28 255
2024 Q2 129,502,142 $2,475,760,428 +$40,167,326 $19.12 239
2024 Q1 125,850,762 $4,125,692,137 -$4,762,881 $32.79 247
2023 Q4 126,464,041 $4,176,843,783 +$156,108,720 $33.03 232
2023 Q3 122,189,782 $3,342,247,641 +$125,298,418 $27.23 201
2023 Q2 117,663,348 $3,553,501,314 +$168,830,769 $30.30 216
2023 Q1 111,825,275 $3,615,108,333 +$350,007,462 $32.45 237
2022 Q4 101,432,734 $2,846,879,147 +$146,714,497 $28.08 229
2022 Q3 95,515,991 $3,431,522,864 +$214,834,478 $35.93 243
2022 Q2 89,722,827 $2,755,609,040 +$99,219,171 $30.71 207
2022 Q1 86,524,226 $2,793,511,290 +$66,700,981 $32.30 208
2021 Q4 84,687,344 $2,342,026,098 -$26,236,636 $27.67 200
2021 Q3 85,614,905 $2,649,865,771 +$83,228,566 $31.00 205
2021 Q2 83,046,124 $1,753,120,165 +$24,126,478 $21.12 175
2021 Q1 81,962,439 $1,657,194,786 +$54,461,956 $20.20 163
2020 Q4 81,531,166 $1,307,117,041 +$30,502,553 $16.03 153
2020 Q3 79,968,182 $996,864,007 +$91,919,009 $12.41 147
2020 Q2 73,419,664 $521,944,449 -$8,509,221 $7.12 127
2020 Q1 76,262,366 $412,459,741 -$45,659,323 $5.43 144
2019 Q4 84,391,629 $763,718,223 +$19,537,960 $9.05 160
2019 Q3 83,189,885 $598,108,319 +$36,446,789 $7.19 164
2019 Q2 79,612,606 $632,474,946 -$65,435,843 $7.95 176
2019 Q1 80,054,942 $1,007,122,936 -$87,346,992 $12.58 181
2018 Q4 84,343,531 $1,681,537,423 -$4,941,229 $19.95 179
2018 Q3 83,480,362 $2,370,707,599 +$83,198,140 $28.40 184
2018 Q2 81,349,096 $1,712,497,871 +$62,476,305 $21.05 175
2018 Q1 79,341,302 $1,130,145,805 +$51,206,773 $14.25 145
2017 Q4 77,238,335 $950,283,643 -$27,787,288 $12.30 151
2017 Q3 73,756,624 $1,317,768,623 +$165,302,431 $17.80 161
2017 Q2 61,976,434 $1,571,057,213 +$516,654,926 $25.35 163
2017 Q1 41,564,536 $920,662,382 +$288,907,012 $22.30 131
2016 Q4 29,423,943 $435,469,686 -$1,463,761 $14.80 116
2016 Q3 27,318,932 $672,581,312 +$205,110,750 $24.62 109
2016 Q2 17,955,627 $344,747,539 +$34,816,467 $19.20 77
2016 Q1 16,464,327 $173,856,000 +$3,040,299 $10.56 69
2015 Q4 16,088,789 $194,836,902 +$1,686,845 $12.11 67
2015 Q3 15,782,348 $251,887,856 +$9,524,041 $15.96 69
2015 Q2 14,783,450 $288,279,132 +$288,279,132 $19.50 62